Drug intelligence / Profile preview

linplixab

Development stage: Preclinical
Lead developer: Chongqing Natural Science Foundation Innovation Group Science Foundation
Modality: Small Molecules
Administration: Oral

Overview

Linplixab is a small molecule drug that acts as a PI3Kδ inhibitor. It is currently being investigated in a randomized, controlled clinical study for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). The drug is administered orally, with doses ranging from 40-80 mg/day. Its mechanism of action involves modulating the PI3Kδ pathway, which is implicated in immune responses relevant to cGVHD.

Other names: 林普利塞

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on linplixab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on linplixab.

Explore the full profile